Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CD38 | P28907 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL801587 | 0.85 | CXCR2 (0.36) | CXCR2 | |
| SCHEMBL12619559 | 0.82 | ALDH1A1 (0.40) | CXCR2MEN1KMT2A | |
| SCHEMBL14164055 | 0.81 | CXCR2 (0.33) | CXCR2HTT | |
| SCHEMBL20611718 | 0.72 | CXCR2 (0.36) | CXCR2MEN1LMNAKMT2A | |
| SCHEMBL12510645 | 0.70 | PDE4B (0.46) | CXCR2MEN1LMNAHTTKMT2A | |
| SCHEMBL23889465 | 0.69 | CXCR2 (0.34) | CXCR2 | |
| SCHEMBL18711828 | 0.69 | CXCR2 (0.34) | CXCR2 | |
| SCHEMBL10266757 | 0.69 | LMNA (0.39) | CXCR2MEN1LMNAHTTKMT2A | |
| SCHEMBL24175625 | 0.67 | USP2 (0.39) | CXCR2USP2 | |
| SCHEMBL24174414 | 0.67 | CXCR2 (0.33) | CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086856-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-14 | — | — | US | disclosed |
| US-7863282-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100256170-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-07 | — | — | US | disclosed |
| US-7473691-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-01-06 | — | — | US | disclosed |
| US-20070179133-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256170-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, CDK3, GSK3A | CXCR2 2405/4885MEN1 2949/4885LMNA 4218/4885 |
| US-20070179133-A1 | Compositions useful as inhibitors of protein kinases | MAP3K20, PACSIN2, MAP3K6 | CXCR2 1558/4885MEN1 1855/4885LMNA 1929/4885 |
| US-20110086856-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, PACSIN2, MAP3K6 | CXCR2 1558/4885MEN1 1855/4885LMNA 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.